Success Metrics

Clinical Success Rate
89.7%

Based on 26 completed trials

Completion Rate
90%(26/29)
Active Trials
22(33%)
Results Posted
4%(1 trials)
Terminated
3(5%)

Phase Distribution

Ph phase_4
2
3%
Ph not_applicable
8
12%
Ph phase_2
2
3%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
2(16.7%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
8(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

26 of 30 finished

Non-Completion Rate

13.3%

4 ended early

Currently Active

22

trials recruiting

Total Trials

66

all time

Status Distribution
Active(33)
Completed(26)
Terminated(4)
Other(3)

Detailed Status

Completed26
Recruiting16
Enrolling by invitation8
Active, not recruiting6
unknown3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
66
Active
22
Success Rate
89.7%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (16.7%)
Phase 42 (16.7%)
N/A8 (66.7%)

Trials by Status

unknown35%
enrolling_by_invitation812%
terminated35%
recruiting1624%
withdrawn12%
active_not_recruiting69%
completed2639%
not_yet_recruiting35%

Recent Activity

Clinical Trials (66)

Showing 20 of 66 trialsScroll for more
NCT04154332

Exosome Cargo From Preeclampsia Patients

Recruiting
NCT05937815Not Applicable

Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor

Recruiting
NCT07655375Not Applicable

Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut

Not Yet Recruiting
NCT04782336

Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test

Completed
NCT04097158

Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone

Recruiting
NCT05467930

CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2

Active Not Recruiting
NCT01937039

Johns Hopkins Breast Cancer Program Longitudinal Repository

Active Not Recruiting
NCT05133102

Longitudinal Oral Microbiome Sampling for BE

Recruiting
NCT07296965

Oral Microbiome in Carotid Atherosclerosis

Recruiting
NCT06861647

iSITE: Investigation of Somatic Alterations in Tumours of the Eye

Completed
NCT05501093

Diabetes Reversal and the Subgingival Microbiota

Completed
NCT05643014

Observational Study of Exposure to Environmental Toxicants Among Firefighters

Recruiting
NCT07416942

Omics of Rituximab-resistance

Not Yet Recruiting
NCT04312308

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Completed
NCT02177721Phase 4

Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario

Not Yet Recruiting
NCT04403880

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

Completed
NCT07326150

Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer

Active Not Recruiting
NCT07271823

Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer

Active Not Recruiting
NCT04113733

Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas

Active Not Recruiting
NCT06851052

SMS - Study of Somatic Mutations Using Genome Sequencing

Enrolling By Invitation

Drug Details

Intervention Type
OTHER
Total Trials
66